1.1
Mirdametinib can be used as an option to treat symptomatic, inoperable plexiform neurofibromas associated with neurofibromatosis type 1 (NF1) in children and young people aged 2 to 17 years. Mirdametinib can only be used if the company provides it according to the commercial arrangement.